Semaglutide — the active ingredient in Ozempic and Wegovy — has become widely known for its effects on body weight and metabolic health. Retatrutide is a newer investigational compound with a broader mechanism of action. Both are administered by injection and both produce meaningful changes in body composition when used under physician supervision.
At Alpha Medical, all peptide-based metabolic protocols are physician-supervised. This comparison is for educational purposes to help patients understand the landscape before their consultation.
How They Work Differently
Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone to regulate appetite, slow gastric emptying, and improve insulin signalling. It has robust clinical evidence and regulatory approval for weight management.
Retatrutide is a triple agonist — targeting GLP-1, GIP, and glucagon receptors simultaneously. This broader mechanism produces more pronounced effects on energy expenditure in addition to appetite regulation. Early clinical data suggests greater weight reduction compared to semaglutide alone, though it remains investigational and is not yet approved by major regulatory agencies.
- Semaglutide: GLP-1 agonist — appetite regulation, gastric slowing, insulin sensitisation
- Retatrutide: triple agonist (GLP-1 + GIP + glucagon) — broader metabolic effect
- Both: administered by weekly subcutaneous injection
- Both: require physician supervision and a structured protocol
The Patient Experience: Results and Expectations
Patients on semaglutide typically notice reduced appetite within the first weeks of treatment. Weight changes are gradual and steady. Side effects — primarily nausea and GI discomfort — are most common during dose escalation and tend to improve over time.
Retatrutide clinical trial participants reported larger overall reductions in body weight and BMI, though the side effect profile is similar. As it is investigational, availability is more limited and protocols require careful physician oversight.
Which Is Right for You?
The choice between these compounds — and whether either is appropriate — is a clinical decision made in consultation with your physician. Semaglutide has the strongest regulatory track record. Retatrutide may be appropriate for patients who have plateau'd on semaglutide or who are candidates for more aggressive metabolic intervention.
At Alpha Medical, all metabolic peptide protocols are tailored individually and supervised by physicians with dedicated expertise in this area.
Ready to take the next step? Book a consultation at our contact page — or request an introductory Medical Aesthetics guide below.
